Physician profile
John B Baird
NPI 1659363919
$2,958.90
in general payments reported to CMS, 2019-2025
28 companies · $732 in 2025
The $732 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $153 · 2021: $149 · 2022: $396 · 2023: $348 · 2024: $854 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,934.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $592.37 | 2020-2025 | |
| Boston Scientific Corporation | $552.97 | 2019-2024 | Bodyguardian, Watchman Access System |
| Amgen INC. | $285.12 | 2020-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $245.08 | 2019-2024 | Xarelto |
| Biotronik INC. | $243.61 | 2024-2025 | Biomonitor, Amvia Edge |
| Novo Nordisk INC | $176.52 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $111.62 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $99.04 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $93.71 | 2022-2025 | Verquvo |
| Pfizer INC. | $65.95 | 2019-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $65.40 | 2024 | Arcalyst |
| Genzyme Corporation | $60.29 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $45.39 | 2024-2025 | Wainua, Farxiga |
| Sanofi-Aventis U.S. LLC | $42.08 | 2019-2024 | |
| Abiomed | $41.76 | 2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $37.76 | 2024 | Evkeeza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.20 | 2023 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.39 | 2023 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $18.84 | 2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $18.17 | 2025 | Amvuttra |
| Atricure, INC. | $18.14 | 2023 | |
| Daiichi Sankyo INC. | $17.54 | 2023 | Injectafer |
| Chiesi USA, INC. | $15.12 | 2024 | Cleviprex |
| Amarin Pharma, INC. | $14.92 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.69 | 2022 | |
| Medtronic, INC. | $14.64 | 2024 | Aurora Ev-Icd Mri Surescan |
| Glaxosmithkline, LLC. | $13.82 | 2025 | Shingrix |
| Shockwave Medical, INC | $12.76 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Baird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.